Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients With Metastatic Urothelial Carcinoma

BACKGROUND. Outcomes with current chemotherapy in metastatic urothelial carcinoma (MUC) remain poor. Lenalidomide, an antiangiogenic and immunomodulatory agent, enhances the effects of chemotherapy in preclinical studies. In this phase Ib/II study, we sought to determine a tolerable dose of lenalido...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Agarwal, Neeraj, Apolo, Andrea B., Tsao, Che-Kai, Lee, Karen M., Godbold, James H., Soto, Rothschild, Poole, Austin, Gimpel-Tetra, Kiev, Lowe, Nancy, Oh, William K., Galsky, Matthew D.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2014
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4153455/
https://ncbi.nlm.nih.gov/pubmed/25052451
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0153
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados